ストックスクリーナーアプリを入手
15.47
2.21%
-0.3477
前日終値:
$15.82
開ける：
$15.66
24時間の取引高:
618.18K
Relative Volume:
0.39
時価総額：
$1.37B
収益：
$203.45M
当期純損益:
$-351.45M
株価収益率:
-3.4005
EPS:
-4.55
ネットキャッシュフロー:
$-369.41M
1週間 パフォーマンス:
-5.56%
1か月 パフォーマンス:
+8.11%
6か月 パフォーマンス:
-20.50%
1年 パフォーマンス:
+60.31%
1日の値動き範囲:
$15.34
$15.82
1週間の範囲:
$15.34
$17.02
52週間の値動き範囲:
$7.931
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.48 | 1.50B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.55 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.48 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.43 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.22 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.95 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
What analysts say about Travere Therapeutics Inc. stockRapid wealth accumulation - PrintWeekIndia
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
Travere Therapeutics Inc. Stock Analysis and ForecastOutstanding growth strategies - jammulinksnews.com
Is Travere Therapeutics Inc. a good long term investmentFree Consultation - jammulinksnews.com
What drives Travere Therapeutics Inc. stock priceHigh-profit stock alerts - jammulinksnews.com
Nisa Investment Advisors LLC Trims Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Research Analysts Set Expectations for TVTX FY2025 Earnings - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Teacher Retirement System of Texas - Defense World
Q2 EPS Estimates for Travere Therapeutics Lowered by Wedbush - Defense World
what makes travere therapeutics inc. stock price move sharplyTop Momentum Stock Pick - Newser
How Travere Therapeutics Inc. stock performs during market volatilityTrade With Low Risk Exposure - Newser
Why Travere Therapeutics Inc. stock attracts strong analyst attentionCapital Doubling Tips - Newser
What makes Travere Therapeutics Inc. stock price move sharplyFree Investing Community - Newser
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 - BioSpace
What drove TVTX's earnings growth in 2024? - AInvest
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) - MSN
Wealth Enhancement Advisory Services LLC Invests $182,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
(TVTX) Proactive Strategies - news.stocktradersdaily.com
Travere Therapeutics (NASDAQ:TVTX) and Ensysce Biosciences (NASDAQ:ENSC) Head to Head Comparison - Defense World
Travere Therapeutics: A Rare Gem in Kidney Disease Therapies - AInvest
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - PR Newswire
Travere Therapeutics, Inc.(NasdaqGM: TVTX) added to Russell 2000 Growth Index - MarketScreener
Travere Therapeutics Draws Institutional Interest from Armistice Capital, Driehaus, and Wellington - International Business Times
High-Growth Tech Stocks in Biopharma and Networking: Undervalued Gems with Strong Upside - AInvest
Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS Awareness - Insider Monkey
13 Best Biotech Stocks To Invest In Now - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Bluefield Daily Telegraph
(TVTX) On The My Stocks Page - news.stocktradersdaily.com
Rhumbline Advisers Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
What is HC Wainwright’s Estimate for TVTX Q2 Earnings? - Defense World
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day - Black Hills Pioneer
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Leerink Partnrs Has Negative Outlook for TVTX Q4 Earnings - Defense World
Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles - Investing.com Canada
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - Defense World
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
Travere Therapeutics Inc (TVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,784 |
37,553 |
93,126 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
0.39%
0.23%
大文字化:
|
ボリューム (24 時間):